Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep-Oct;143(1-2):108537.
doi: 10.1016/j.ymgme.2024.108537. Epub 2024 Jul 15.

Reduction of neuroinflammation and seizures in a mouse model of CLN1 batten disease using the small molecule enzyme mimetic, N-Tert-butyl hydroxylamine

Zach Fyke  1 , Rachel Johansson  2 , Anna I Scott  3 , Devin Wiley  4 , Daniel Chelsky  4 , Joseph D Zak  5 , Nader Al Nakouzi  6 , Kevin P Koster  7 , Akira Yoshii  8
Affiliations

Reduction of neuroinflammation and seizures in a mouse model of CLN1 batten disease using the small molecule enzyme mimetic, N-Tert-butyl hydroxylamine

Zach Fyke et al. Mol Genet Metab. 2024 Sep-Oct.

Abstract

Infantile neuronal ceroid lipofuscinosis (CLN1 Batten Disease) is a devastating pediatric lysosomal storage disease caused by pathogenic variants in the CLN1 gene, which encodes the depalmitoylation enzyme, palmitoyl-protein thioesterase 1 (PPT1). CLN1 patients present with visual deterioration, psychomotor dysfunction, and recurrent seizures until neurodegeneration results in death, typically before fifteen years of age. Histopathological features of CLN1 include aggregation of lysosomal autofluorescent storage material (AFSM), as well as profound gliosis. The current management of CLN1 is relegated to palliative care. Here, we examine the therapeutic potential of a small molecule PPT1 mimetic, N-tert-butyl hydroxylamine (NtBuHA), in a Cln1-/- mouse model. Treatment with NtBuHA reduced AFSM accumulation both in vitro and in vivo. Importantly, NtBuHA treatment in Cln1-/- mice reduced neuroinflammation, mitigated epileptic episodes, and normalized motor function. Live cell imaging of Cln1-/- primary cortical neurons treated with NtBuHA partially rescued aberrant synaptic calcium dynamics, suggesting a potential mechanism contributing to the therapeutic effects of NtBuHA in vivo. Taken together, our findings provide supporting evidence for NtBuHA as a potential treatment for CLN1 Batten Disease.

Keywords: Batten disease; Infantile neuronal ceroid lipofuscinosis; Neurodegeneration; Neuroinflammation; Palmitoyl-protein thioesterase; Seizure; Small molecule therapeutic; Synapse calcium.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest AIS and DW have stock in Circumvent. NAN, CH, PR and RJ all receive compensation for their time and expertise from Circumvent.

Similar articles

See all similar articles

Cited by

References

    1. Vesa J, Hellsten E, Verkruyse LA, Camp LA, Rapola J, Santavuori P, Hofmann SL, Peltonen L, Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis, Nature 376 (1995) 584–587. 10.1038/376584a0. - DOI - PubMed
    1. Williams RE, Mole SE, New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses, Neurology 79 (2012) 183–191. 10.1212/wnl.0b013e31825f0547. - DOI - PubMed
    1. Nita DA, Mole SE, Minassian BA, Neuronal ceroid lipofuscinoses., Epileptic Disorders 18 (2016). 10.1684/epd.2016.0844. - DOI - PubMed
    1. Haltia M, The Neuronal Ceroid-Lipofuscinoses J Neuropathology Exp Neurology 62 (2003) 1–13. 10.1093/jnen/62.1.1. - DOI - PubMed
    1. Haltia M, The neuronal ceroid-lipofuscinoses: from past to present., Biochimica et Biophysica Acta 1762 (2006) 850–6. 10.1016/j.bbadis.2006.06.010. - DOI - PubMed

MeSH terms

LinkOut - more resources